Suppr超能文献

肺癌患者中的 COVID-19。

COVID-19 in patients with lung cancer.

机构信息

Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA.

Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, USA.

出版信息

Ann Oncol. 2020 Oct;31(10):1386-1396. doi: 10.1016/j.annonc.2020.06.007. Epub 2020 Jun 17.

Abstract

BACKGROUND

Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific features that impact the severity of COVID-19 may inform optimal cancer care during this pandemic.

PATIENTS AND METHODS

We examined consecutive patients with lung cancer and confirmed diagnosis of COVID-19 (n = 102) at a single center from 12 March 2020 to 6 May 2020. Thresholds of severity were defined a priori as hospitalization, intensive care unit/intubation/do not intubate ([ICU/intubation/DNI] a composite metric of severe disease), or death. Recovery was defined as >14 days from COVID-19 test and >3 days since symptom resolution. Human leukocyte antigen (HLA) alleles were inferred from MSK-IMPACT (n = 46) and compared with controls with lung cancer and no known non-COVID-19 (n = 5166).

RESULTS

COVID-19 was severe in patients with lung cancer (62% hospitalized, 25% died). Although severe, COVID-19 accounted for a minority of overall lung cancer deaths during the pandemic (11% overall). Determinants of COVID-19 severity were largely patient-specific features, including smoking status and chronic obstructive pulmonary disease [odds ratio for severe COVID-19 2.9, 95% confidence interval 1.07-9.44 comparing the median (23.5 pack-years) to never-smoker and 3.87, 95% confidence interval 1.35-9.68, respectively]. Cancer-specific features, including prior thoracic surgery/radiation and recent systemic therapies did not impact severity. Human leukocyte antigen supertypes were generally similar in mild or severe cases of COVID-19 compared with non-COVID-19 controls. Most patients recovered from COVID-19, including 25% patients initially requiring intubation. Among hospitalized patients, hydroxychloroquine did not improve COVID-19 outcomes.

CONCLUSION

COVID-19 is associated with high burden of severity in patients with lung cancer. Patient-specific features, rather than cancer-specific features or treatments, are the greatest determinants of severity.

摘要

背景

患有肺癌的患者可能会出现不成比例的严重 2019 冠状病毒病(COVID-19)结局。了解影响 COVID-19 严重程度的患者特异性和癌症特异性特征,可能有助于在大流行期间为癌症患者提供最佳的治疗。

方法

我们对 2020 年 3 月 12 日至 2020 年 5 月 6 日期间在一家单中心确诊患有肺癌和 COVID-19 的连续患者(n=102)进行了检查。预先定义了严重程度的阈值,住院、重症监护病房/插管/不插管(ICU/插管/DNI,严重疾病的综合指标)或死亡。康复定义为 COVID-19 检测后 >14 天且症状缓解后 >3 天。从 MSK-IMPACT(n=46)推断了人类白细胞抗原(HLA)等位基因,并与患有肺癌且无已知非 COVID-19 的对照组(n=5166)进行了比较。

结果

肺癌患者的 COVID-19 较为严重(62%住院,25%死亡)。尽管病情严重,但 COVID-19 在大流行期间仅占肺癌总死亡人数的一小部分(总体为 11%)。COVID-19 严重程度的决定因素主要是患者的特定特征,包括吸烟状况和慢性阻塞性肺疾病[严重 COVID-19 的比值比(OR),与从不吸烟者相比,中位数(23.5 包年)为 2.9(95%置信区间(CI)为 1.07-9.44),与从未吸烟者相比为 3.87(95%CI 为 1.35-9.68)]。癌症特异性特征,包括先前的胸部手术/放疗和最近的全身治疗,并未影响严重程度。与非 COVID-19 对照组相比,COVID-19 轻症或重症患者的人类白细胞抗原超型通常相似。大多数患者从 COVID-19 中康复,包括 25%最初需要插管的患者。在住院患者中,羟氯喹并未改善 COVID-19 结局。

结论

COVID-19 与肺癌患者的严重程度负担高有关。患者的特定特征,而不是癌症的特定特征或治疗方法,是严重程度的最大决定因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b00/7297689/426e5f5b31e7/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验